Psoralen from Sigma-Aldrich
CleanBox DNA Workstation from Bio-Rad
Mouse Anti-Human VRK2 Monoclonal Antibody, Unconjugated, Clone 3B10 from Abnova Corporation
Mouse Anti-Human PPIL2 Monoclonal Antibody, Unconjugated, Clone 2E11 from Abnova Corporation
Biology Products:...rs, affecting the number and variety of some of th...tudy has found. , Rivers and streams are key ecos... links with surrounding habitats, yet little empha...s of climate change on these running-waters. ,...central Wales, led by Professor Steve Ormerod and ...
...m magnetic resonance imaging (MRI) to computed tom...d organs have become the primary tools physicians ...or effective treatment. , New, innovative data d...ty will provide doctors with a dramatically improv...monly used. This patent-pending technology allows ...
...ne system from launching an all-out fight against ...trient "floodgate" that serves to protect against ...gs appear in the May 4, 2007 issue of the journal ...rs found that animals lacking a protein enriched i...tion in deep pockets of visceral fat. The animals ...
Other Biology News:Novel system developed to turn data into real-time, interactive 3-D images 2Keeping the immune system from starting a 'food fight' 2(Date:11/6/2009)... 6 Intarcia Therapeutics, Inc. del...ROS® continuous delivery of exenatide) progra...h Annual Diabetes Technology Meeting in San Franci...bin/prnh/20050301/SFTU126LOGO ) ,, Continuous...owers Plasma Glucose, HbA1c and Reduces Weight in ...
(Date:11/5/2009)...v. 5 GenVec, Inc. (Nasda...or the third quarter ended September 30, 2009. Gen... share) for the three months ended September 30, 2...per share) in the comparable quarter of 2008. For ... net loss was $14.1 million ($0.15 per share), com...
(Date:11/5/2009)...Newswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulle...ncer, President and CEO of Imagenetix, will be pre...ICRO Conference on Thursday, December 3rd, at 10:3...About LD MICRO ,, LD MICRO is a by-invitation o...alued companies in the micro-cap space. Since 2002...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC B...ults for the quarter ended September 30, 2009. The...tables that follow. ,, Third Quarter 2009 ,...$0.01 per share for the third quarter of 2009 as c...re for the third quarter of 2008. ,, Net sales...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7